$ABBV News

AbbVie Still Has Room To Run

AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

AbbVie To Present New Data From Its ABBV-1480 PD-1/VEGF Bispecific Antibody In Frontline Non-Small Cell Lung Cancer At 2026 World Conference On Lung Cancer

Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead

Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303

Billionaire Ken Griffin Increased His Position in This Dividend King by 547%

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300

Wolfe Research Upgrades AbbVie (ABBV)

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target

AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment

AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?

BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247

Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?